目的幽门螺杆菌（Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ，Ｈｐ）是慢性胃炎、消化性溃疡的主要致病因素之一。本研究旨在通过对奥美拉唑（ＯＭＥ）和呋喃唑酮（ＦＺ）联合用药的疗效观察以寻求一种有效、方便的疗法。方法病例选择：经胃镜检查确诊的慢性胃炎或十二指肠球部溃疡且Ｈｐ检测阳性的患者，经过纳入标准及排除标准的筛选而进入研究。分组治疗：病例随机分为三个治疗组，治疗组１（２３人）：ＯＭＥ２０ｍｇｑｄ＋ＦＺ０．２ｇｂｉｄ；治疗组２（２５人）：ＯＭＥ２０ｍｇｑｄ＋ＦＺ０．２ｇｔｉｄ；治疗组３（２６人）：ＯＭＥ２０ｍｇｂｉｄ＋ＦＺ０．２ｇｔｉｄ，疗程均为７天。其中十二指肠球部溃疡病人ＯＭＥ按各自剂量再服一周。停药四周后做１３Ｃ－尿素呼气试验。结果７４例患者进入研究。治疗组１有２２人完成全疗程，根除率８６４％；治疗组２为１８人，根除率８３３％；治疗组３为１９人，根除率７８９％。治疗组２、３（ＦＺ０２ｇｔｉｄ）与治疗组１（ＦＺ０２ｇｂｉｄ）之间根除率的差异无显著意义，但不良反应发生率明显增加。结论本研究显示方案一不良反应发生率低，依从性好，疗效达到８６４％；依从性是影响根除率高低的重要因素；体外试验显示Ｈｐ对呋喃唑酮? Objective Helicobacter pylori (Hp) is one of the main causative agents of chronic gastritis and peptic ulcer. This study aimed to find an effective and convenient therapy by observing the curative effect of omeprazole (OME) and furazolidone (FZ). Methods Case Selection: Gastroscopy confirmed chronic gastritis or duodenal ulcer and Hp test positive patients, after inclusion criteria and exclusion criteria into the study. Treatment group 2 (25): OME 20mgqd + FZ0.2gtid; Treatment group 3 (26): OME 20mgbid + FZ0.2gtid, treatment were 1 (23): treatment group 2 For 7 days. One of the patients with duodenal ulcer patients were given one dose of OME for another week. Four weeks after stopping drug do 13C-urea breath test. Results 74 patients entered the study. In treatment group 1, 22 people completed the whole course of treatment, the eradication rate was 86.4%; treatment group 2 was 18, the eradication rate was 833%; treatment group 3 was 19, and the eradication rate was 789%. There was no significant difference in the eradication rates between treatment groups 2 and 3 (FZ02gtid) and treatment group 1 (FZ02gbid), but the incidence of adverse reactions increased significantly. Conclusions This study shows that the incidence of adverse reactions is low and the compliance is 864%. Compliance is the most important factor influencing the eradication rate. In vitro experiments showed that the effects of Hp on furazolidone,